Literature DB >> 12631678

Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.

C J Hawkey1, M J S Langman.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are well recognised as causing peptic ulceration and ulcer complications. However, several critical issues, including the amount of both gastrointestinal and non-gastrointestinal disease affected by NSAIDs, their interaction with ancillary risk factors, and how to optimise management in subgroups, remain poorly understood. In this article, strategies for subgroups that take account of non-specific gastrointestinal risks, minimisation of residual risk, and the importance of non-gastrointestinal toxicity are suggested, and areas for research identified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631678      PMCID: PMC1773617          DOI: 10.1136/gut.52.4.600

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  96 in total

1.  A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.

Authors:  L Laine; S Harper; T Simon; R Bath; J Johanson; H Schwartz; S Stern; H Quan; J Bolognese
Journal:  Gastroenterology       Date:  1999-10       Impact factor: 22.682

Review 2.  Causes of peptic ulcer. A selective epidemiologic review.

Authors:  M Usser
Journal:  J Chronic Dis       Date:  1967-06

3.  Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.

Authors:  L S Simon; A L Weaver; D Y Graham; A J Kivitz; P E Lipsky; R C Hubbard; P C Isakson; K M Verburg; S S Yu; W W Zhao; G S Geis
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

4.  Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.

Authors:  M J Langman; D M Jensen; D J Watson; S E Harper; P L Zhao; H Quan; J A Bolognese; T J Simon
Journal:  JAMA       Date:  1999-11-24       Impact factor: 56.272

5.  Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects.

Authors:  J Rossat; M Maillard; J Nussberger; H R Brunner; M Burnier
Journal:  Clin Pharmacol Ther       Date:  1999-07       Impact factor: 6.875

6.  Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data.

Authors:  S C Lewis; M J S Langman; Joan-Ramon Laporte; John N S Matthews; Michael D Rawlins; Bengt-Erik Wiholm
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

7.  Aspirin, paracetamol, and haematemesis and melaena.

Authors:  D Coggon; M J Langman; D Spiegelhalter
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

8.  A biochemical basis for the gastrointestinal toxicity of non-steroid antirheumatoid drugs.

Authors:  B J Whittle; J R Vane
Journal:  Arch Toxicol Suppl       Date:  1984

9.  Association of adrenocorticosteroid therapy and peptic-ulcer disease.

Authors:  J Messer; D Reitman; H S Sacks; H Smith; T C Chalmers
Journal:  N Engl J Med       Date:  1983-07-07       Impact factor: 91.245

10.  Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage.

Authors:  M J Langman; L Morgan; A Worrall
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-02
View more
  42 in total

1.  New dogmas or old?

Authors:  B J R Whittle
Journal:  Gut       Date:  2003-09       Impact factor: 23.059

Review 2.  Impact of safety-related regulatory action on clinical practice: a systematic review.

Authors:  Sigrid Piening; Flora M Haaijer-Ruskamp; Jonie T N de Vries; Menno E van der Elst; Pieter A de Graeff; Sabine M J M Straus; Peter G M Mol
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

3.  Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly.

Authors:  Kathrine F Vandraas; Olav Spigset; Milada Mahic; Lars Slørdal
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

4.  Evaluation and management of dyspepsia.

Authors:  R Christopher Harmon; David A Peura
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

Review 5.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

Review 6.  Which drugs cause preventable admissions to hospital? A systematic review.

Authors:  R L Howard; A J Avery; S Slavenburg; S Royal; G Pipe; P Lucassen; M Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06-26       Impact factor: 4.335

7.  Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.

Authors:  C J Hawkey; G M Hawkey; S Everitt; M M Skelly; W A Stack; D Gray
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 8.  Use of prescription drugs in athletes.

Authors:  Antti Alaranta; Hannu Alaranta; Ilkka Helenius
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

Review 9.  Delayed-release lansoprazole plus naproxen.

Authors:  Monique P Curran; Keri Wellington
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Adverse drug reactions experience in a teaching hospital in Jordan.

Authors:  Mohammed Alsbou; Sameh Alzubiedi; Hamed Alzobi; Nawal Abu Samhadanah; Yousef Alsaraireh; Omar Alrawashdeh; Amin Aqel; Khalil Al-Salem
Journal:  Int J Clin Pharm       Date:  2015-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.